- Home
- ALVR vs IKNA Comparison
ALVR vs IKNA Comparison
Compare ALVR & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVR
- IKNA
- Stock Information
- Founded
- ALVR 2013
- IKNA 2016
- Country
- ALVR United States
- IKNA United States
- Employees
- ALVR N/A
- IKNA N/A
- Industry
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- ALVR Health Care
- IKNA Health Care
- Exchange
- ALVR Nasdaq
- IKNA Nasdaq
- Market Cap
- ALVR 87.7M
- IKNA 83.0M
- IPO Year
- ALVR 2020
- IKNA 2021
- Fundamental
- Price
- ALVR $0.94
- IKNA $1.68
- Analyst Decision
- ALVR Sell
- IKNA Buy
- Analyst Count
- ALVR 5
- IKNA 2
- Target Price
- ALVR $1.00
- IKNA $3.00
- AVG Volume (30 Days)
- ALVR 155.6K
- IKNA 41.6K
- Earning Date
- ALVR 11-04-2024
- IKNA 11-07-2024
- Dividend Yield
- ALVR N/A
- IKNA N/A
- EPS Growth
- ALVR N/A
- IKNA N/A
- EPS
- ALVR N/A
- IKNA N/A
- Revenue
- ALVR N/A
- IKNA $1,844,000.00
- Revenue This Year
- ALVR N/A
- IKNA N/A
- Revenue Next Year
- ALVR N/A
- IKNA N/A
- P/E Ratio
- ALVR N/A
- IKNA N/A
- Revenue Growth
- ALVR N/A
- IKNA N/A
- 52 Week Low
- ALVR $0.58
- IKNA $1.02
- 52 Week High
- ALVR $2.49
- IKNA $4.63
- Technical
- Relative Strength Index (RSI)
- ALVR 69.10
- IKNA 51.57
- Support Level
- ALVR $0.74
- IKNA $1.68
- Resistance Level
- ALVR $0.91
- IKNA $1.78
- Average True Range (ATR)
- ALVR 0.06
- IKNA 0.04
- MACD
- ALVR 0.01
- IKNA 0.00
- Stochastic Oscillator
- ALVR 94.50
- IKNA 36.36
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.